Hospital
Dickenson Community Hospital, INC.
Dickenson Community Hospital, INC. was paid $6.94M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoDICKENSON COMMUNITY HOSPITAL, INC.
CLINTWOOD, VA 24228
CLINTWOOD, VA 24228
33aNPI1285685727assigned 05/12/2006
33bProvider typeCritical Access Hospital
28Total paid$6.94M
24GClaims142,384
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Virginia
Rank by total paid#3 of 8
Median peer was paid$893K
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,051 | $384K | |
| 2019 | 22,437 | $662K | |
| 2020 | 18,098 | $862K | |
| 2021 | 20,177 | $1.06M | |
| 2022 | 22,334 | $1.28M | |
| 2023 | 25,256 | $1.63M | |
| 2024incomplete | 16,031 | $1.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 8,992 | 7,915 | $2.09M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 6,847 | 6,086 | $1.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 4,280 | 3,709 | $890K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 2,073 | 1,758 | $872K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.1% | 3,399 | 3,100 | $282K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.2% | 1,451 | 1,319 | $225K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 826 | 758 | $223K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 1,206 | 1,108 | $206K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.5% | 1,519 | 1,341 | $175K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 449 | 415 | $121K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 1,284 | 1,128 | $104K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 276 | 252 | $76K |
89 more codes
| 80053 | Comprehensive metabolic panel | <1% | 11,047 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 607 | $46K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 258 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,943 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 107 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 750 | $35K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,052 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,290 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 896 | $19K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 195 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,744 | $16K |
| 80061 | Lipid panel | <1% | 2,316 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,810 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,382 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,844 | $10K |
| 87040 | <1% | 1,421 | $9K | |
| 72100 | <1% | 299 | $8K | |
| 83880 | <1% | 748 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 490 | $7K |
| 84484 | <1% | 3,962 | $5K | |
| 85027 | <1% | 1,259 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,495 | $5K |
| 81001 | <1% | 4,720 | $4K | |
| 84439 | <1% | 577 | $4K | |
| 82607 | <1% | 641 | $4K | |
| 87077 | <1% | 1,585 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,005 | $3K |
| 73562 | <1% | 117 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,110 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,212 | $2K |
| J3490 | Unclassified drugs | <1% | 704 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 866 | $2K |
| 83605 | <1% | 2,313 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,861 | $2K |
| 74018 | <1% | 85 | $2K | |
| 80306 | <1% | 720 | $2K | |
| 81003 | <1% | 2,313 | $2K | |
| 80329 | <1% | 84 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 117 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 28 | $1K |
| 87088 | <1% | 782 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,501 | $1K |
| 73610 | <1% | 77 | $873.86 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,682 | $850.74 |
| 81025 | <1% | 1,671 | $840.83 | |
| 85610 | <1% | 912 | $832.62 | |
| 73630 | <1% | 29 | $783.04 | |
| 83735 | <1% | 1,217 | $703.98 | |
| 85379 | <1% | 288 | $641.39 | |
| 80320 | <1% | 176 | $564.41 | |
| 80143 | <1% | 128 | $548.08 | |
| 99406 | <1% | 14 | $517.82 | |
| 83690 | <1% | 1,755 | $513.52 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 30 | $451.94 |
| 90715 | <1% | 14 | $448.41 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 20 | $413.94 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 67 | $380.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,924 | $366.78 |
| 80179 | <1% | 130 | $325.63 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,217 | $323.41 |
| 87186 | <1% | 519 | $280.26 | |
| 80076 | <1% | 127 | $277.16 | |
| 96376 | <1% | 366 | $234.60 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 28 | $220.96 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,109 | $161.88 |
| 82140 | <1% | 57 | $141.86 | |
| 87081 | <1% | 661 | $101.78 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 742 | $99.44 |
| 94761 | <1% | 417 | $76.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 545 | $74.97 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 483 | $58.36 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $51.31 |
| 82150 | <1% | 29 | $37.38 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 391 | $30.64 |
| 85730 | <1% | 106 | $27.28 | |
| 82043 | <1% | 12 | $21.90 | |
| 87070 | <1% | 15 | $21.00 | |
| 82248 | <1% | 17 | $20.82 | |
| 82570 | <1% | 12 | $17.17 | |
| 84100 | <1% | 77 | $12.43 | |
| 87205 | <1% | 15 | $10.48 | |
| 87807 | <1% | 99 | $8.19 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 193 | $6.54 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 30 | $3.33 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $0.43 |
| 82803 | 0% | 15 | $0.00 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 51 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILTON, SHANE (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.